COMMUNIQUÉS West-GlobeNewswire

BiomX Issues Statement Regarding Recent Common Stock Trading Activity
27/01/2026
NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific [...]
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
27/01/2026
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
27/01/2026
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday [...]
The Association of American Physicians and Surgeons (AAPS) Supports ACIP Vaccine Panel Chairman, Kirk Milhoan, M.D.
27/01/2026
TUCSON, Ariz., Jan. 27, 2026 (GLOBE NEWSWIRE) -- In response to a January 23 New York Times article strongly criticizing pediatric cardiologist Kirk Milhoan, M.D., appointed by HHS Secretary Robert F. Kennedy, Jr., to [...]
Vivani Medical, Inc. Announces Closing of Common Stock Offering
27/01/2026
ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
27/01/2026
Proposed $1.0 million Convertible Debenture and concurrent $500,000 Private Placement Intended to Support Near-Term Operations Board and Management Enhancements Strengthen Governance and Capital Markets Execution [...]
Vystar to Acquire Stake in GoPaid and Partner with Capital R3alm to Launch R3alm Oracle and Collectibles Platform
27/01/2026
Worcester, Massachusetts, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vystar Corporation (OTCQB: VYST ), a diversified innovation company with operations spanning eco-friendly products and collectibles monetization, today [...]
U.S. Neurology Associates Affiliates with Texas Institute for Neurological Disorders, a Premier Neurology Practice in Dallas-Fort Worth
27/01/2026
DALLAS and FORT WORTH, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- U.S. Neurology Associates (USNA), a physician services organization dedicated to enhancing community-based neurology care, today announced its affiliation [...]
Eurobio Scientific : chiffre d'affaires 2025
27/01/2026
EXERCICE 2025, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires annuel de 9% à 168 M€ Déploiement de la stratégie du Groupe : Produits propriétaires : 35% du Chiffre d’affaires [...]
Patterson Veterinary Relaunches a Refreshed NaVetor Veterinary Cloud Software After Acquiring Full Rights
27/01/2026
Reinforces long-term commitment to innovative software with flexible options for growing practices ST. PAUL, Minn., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Patterson Veterinary announced it has acquired full ownership of [...]
Eurobio Scientific: 2025 FY revenue
27/01/2026
FISCAL YEAR 2025, CONFIRMATION OF STRATEGIC TRANSFORMATION 9% increase in annual revenue to €168 million Deployment of the Group's strategy: Proprietary products: 35% of revenue Internationalization: 42% of revenue [...]
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN
27/01/2026
Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia [...]
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
27/01/2026
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a [...]
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
27/01/2026
ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas [...]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
27/01/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p- [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a [...]

Pages